DCT

1:26-cv-08939

Novo Nordisk Inc v. Cipla Ltd

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: Novo Nordisk Inc. v. Cipla Ltd., 1:26-cv-08939, D.N.J., 08/13/2026
  • Venue Allegations: Venue is alleged to be proper as to Cipla USA, Inc. because it has a regular and established place of business in New Jersey and submitted its Abbreviated New Drug Application (ANDA) from its New Jersey headquarters. Venue is alleged to be proper as to Cipla Ltd. as a non-U.S. resident, permitting suit in any judicial district.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an ANDA to the FDA seeking approval to market a generic version of Plaintiff's Ozempic® (semaglutide) product constitutes an act of infringement of four U.S. patents.
  • Technical Context: The technology involves GLP-1 receptor agonists, specifically the compound semaglutide and methods of its use, for the treatment of type 2 diabetes and related cardiovascular conditions.
  • Key Procedural History: This is a Hatch-Waxman action initiated within 45 days of Plaintiff's receipt of a notice letter from Defendant. The letter contained a Paragraph IV certification asserting that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by the proposed generic product.

Case Timeline

Date Event
2005-03-18 '343 Patent Priority Date
2012-03-06 U.S. Patent No. 8,129,343 Issues
2012-07-01 '462 Patent Priority Date
2016-04-28 '543 Patent Priority Date
2017-10-12 '988 Patent Priority Date
2019-07-02 U.S. Patent No. 10,335,462 Issues
2025-05-13 U.S. Patent No. 12,295,988 Issues
2026-03-10 U.S. Patent No. 12,569,543 Issues
2026-06-05 Cipla sends first Notice Letter to Novo Nordisk
2026-07-24 Cipla sends second Notice Letter to Novo Nordisk
2026-08-13 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,129,343 - "Acylated GLP-1 Compounds"

  • Patent Identification: U.S. Patent No. 8,129,343, "Acylated GLP-1 Compounds", issued March 6, 2012. Compl. ¶15

The Invention Explained

  • Problem Addressed: The patent addresses the need for therapeutic GLP-1 compounds with a longer duration of action in vivo to reduce dosing frequency for diabetes patients, many of whom experience "needle-phobia" with injectable treatments. '343 Patent, col. 1:49-65
  • The Patented Solution: The invention is a modified GLP-1 analogue that is chemically stabilized against degradation by the DPP-IV enzyme and is acylated with a specific moiety. This moiety, which includes an albumin-binding residue and a linker, allows the compound to bind to albumin in the bloodstream, thereby extending its half-life and protracting its therapeutic effect. '343 Patent, col. 2:1-5 '343 Patent, col. 5:19-25 '343 Patent, col. 6:29-37
  • Technical Importance: This technology enabled the development of a GLP-1 therapy (semaglutide) that could be administered on a weekly basis, rather than daily, significantly improving convenience and potential patient adherence. '343 Patent, col. 1:60-67

Key Claims at a Glance

  • The complaint asserts claims 1-6. Compl. ¶29 Independent claims 1 and 3 are foundational.
  • Independent Claim 1 (a compound claim) recites a specific chemical structure comprising:
    • A GLP-1 analogue peptide backbone: [Aib8,Arg34]GLP-1-(7-37).
    • An acylated moiety attached to the lysine residue at position 26.
    • The structure of the acylated moiety, which corresponds to semaglutide.
  • Independent Claim 3 (a method claim) recites:
    • A method for treating type 2 diabetes in a subject.
    • Comprising administering an effective amount of a compound of claim 1.

U.S. Patent No. 10,335,462 - "Use of Long-Acting GLP-1 Peptides"

  • Patent Identification: U.S. Patent No. 10,335,462, "Use of Long-Acting GLP-1 Peptides", issued July 2, 2019. Compl. ¶16

The Invention Explained

  • Problem Addressed: The patent describes a need for GLP-1 agonist therapies that provide an improved effect on glycemic control (HbA1c reduction) and body weight reduction compared to existing treatments. '462 Patent, col. 2:51-59
  • The Patented Solution: The invention provides a method of treatment using specific dosage regimens of a long-acting GLP-1 agonist, such as semaglutide. The patent discloses that administering semaglutide once weekly in an amount of at least 0.7 mg provides a surprisingly improved reduction of HbA1c and body weight. '462 Patent, abstract '462 Patent, col. 3:1-3 '462 Patent, Fig. 1
  • Technical Importance: The invention established a specific, clinically superior dosing regimen for semaglutide that demonstrated improved efficacy for treating type 2 diabetes and obesity compared to then-available therapies. '462 Patent, col. 2:60-66

Key Claims at a Glance

  • The complaint asserts claims 1-10. Compl. ¶36 Independent claim 1 is foundational.
  • Independent Claim 1 recites:
    • A method for treating type 2 diabetes.
    • Comprising administering semaglutide once weekly.
    • In an amount of 1.0 mg.
    • To a subject in need thereof.

Multi-Patent Capsule: U.S. Patent No. 12,295,988 - "Semaglutide in Medical Therapy"

  • Patent Identification: U.S. Patent No. 12,295,988, "Semaglutide in Medical Therapy", issued May 13, 2025. Compl. ¶17
  • Technology Synopsis: The patent addresses the need for effective weight management therapies for obese or overweight individuals. It discloses a method of using semaglutide at specific high dosages (e.g., 2.0-4.0 mg once weekly) to achieve substantial body weight loss, claiming an unexpectedly favorable ratio between weight reduction efficacy and gastrointestinal side effects. '988 Patent, abstract '988 Patent, col. 2:29-45
  • Asserted Claims: Claim 1 is asserted. Compl. ¶43
  • Accused Features: The complaint alleges that Cipla's ANDA submission for a generic semaglutide product constitutes infringement, as the product would be used for weight management in accordance with the patented method. Compl. ¶¶42-43

Multi-Patent Capsule: U.S. Patent No. 12,569,543 - "Semaglutide in Cardiovascular Conditions"

  • Patent Identification: U.S. Patent No. 12,569,543, "Semaglutide in Cardiovascular Conditions", issued March 10, 2026. Compl. ¶18
  • Technology Synopsis: The patent addresses the high risk of cardiovascular disease in patients with type 2 diabetes. It discloses methods of using semaglutide to reduce the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction or non-fatal stroke, in this high-risk patient population. '543 Patent, abstract '543 Patent, col. 1:20-34
  • Asserted Claims: Claims 1-13 are asserted. Compl. ¶50
  • Accused Features: The complaint alleges that Cipla's ANDA submission infringes because the proposed generic product would be prescribed to reduce cardiovascular risk in diabetic patients, thereby practicing the patented method. Compl. ¶¶49-50

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is "Cipla's Product," a generic version of semaglutide subcutaneous solution in dosage strengths of 2 mg/3 ml, 4 mg/3 ml, and 8 mg/3 ml, for which Cipla has filed ANDA No. 219719. Compl. ¶¶2, 8-9, 23
  • Functionality and Market Context: Cipla's Product is a generic version of Novo Nordisk's Ozempic® and is intended for the same therapeutic indications. Compl. ¶23 These indications include improving glycemic control, reducing the risk of major cardiovascular events, and addressing kidney disease in adults with type 2 diabetes. Compl. ¶19 Compl. ¶23 Cipla's ANDA relies on the Ozempic® NDA and includes data intended to demonstrate bioequivalence. Compl. ¶24 The filing represents Cipla's intent to commercially manufacture and sell this product in the U.S. prior to the expiration of the patents-in-suit. Compl. ¶13

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

'343 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound of the structure ... [structure of semaglutide] where the amino acid sequence is that of SEQ ID NO: 7. The complaint alleges that Cipla's Product comprises semaglutide. ¶29 col. 129:1-15
  • Identified Points of Contention:
    • Technical Questions: In an ANDA case involving a compound claim, the primary technical question is one of identity: does the active pharmaceutical ingredient in the proposed generic product fall within the structural definition of the claim? Given that Cipla's ANDA must demonstrate bioequivalence to Ozempic® (semaglutide), a dispute on this point may be less likely than a dispute over the patent's validity. Compl. ¶24

'462 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for treating type 2 diabetes, Cipla's ANDA seeks approval to market its product as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ¶23 col. 2:45-46
comprising administering semaglutide once weekly The ANDA seeks approval for a generic version of Ozempic®, which is a once-weekly semaglutide injection. ¶2; ¶23 col. 2:43-44
in an amount of 1.0 mg The ANDA is for dosage strengths that would enable administration of a 1.0 mg weekly dose, and the proposed product label will allegedly instruct such use. ¶23; ¶36 col. 4:42-43
to a subject in need thereof. The product is indicated for adults with type 2 diabetes mellitus. ¶23 col. 2:40-41
  • Identified Points of Contention:
    • Scope Questions: The central issue for infringement of this method-of-use patent will be whether Cipla's proposed product label will instruct or encourage physicians and patients to administer the drug in a manner that meets all limitations of the asserted claims. This raises the question of whether Cipla can and will "carve out" the patented 1.0 mg once-weekly dosing regimen from its label to avoid infringement.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail to identify specific claim terms that are likely to be in dispute for construction purposes. However, based on the nature of the asserted claims, the following term may be a focus.

  • The Term: "administering... in an amount of 1.0 mg" (from claim 1 of the '462 Patent).
  • Context and Importance: Practitioners may focus on this term because the infringement analysis for this method claim depends on what the ANDA filer's proposed label instructs. The defendant may argue its product, available in various strengths Compl. ¶23, does not explicitly instruct administration of exactly "1.0 mg," attempting to design around the claim. The construction of this term-whether it requires precise administration of 1.0 mg or can be read more broadly-could be critical.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification of the '462 patent repeatedly discusses effective weekly amounts of "at least 0.7 mg per week" and provides data for various dosages, which may support an argument that "1.0 mg" is an exemplary, not exclusively limiting, amount within a broader inventive concept of a high-efficacy dosage range. '462 Patent, col. 3:1-3 '462 Patent, Table 1
    • Evidence for a Narrower Interpretation: Claim 1 recites the specific amount "1.0 mg" without using broadening language like "about" or "at least." The patent also includes dependent claims that recite different amounts. A party may argue that this specificity was intentional and that the claim scope should be strictly limited to exactly 1.0 mg per week, distinguishing it from other disclosed and claimed dosages. '462 Patent, claim 1 '462 Patent, claim 7

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Cipla will induce infringement of the asserted method claims. The basis for this allegation is that Cipla's commercial marketing, sale, and product labeling will intentionally encourage and instruct healthcare professionals and patients to use the generic product in a manner that practices the patented methods of treatment. Compl. ¶30 Compl. ¶37 Compl. ¶44 Compl. ¶51
  • Willful Infringement: The complaint does not use the word "willful," but it alleges that Cipla's infringement would occur "with knowledge of" the patents-in-suit. Compl. ¶30 Compl. ¶37 Compl. ¶44 Compl. ¶51 The alleged basis for this knowledge is Cipla's submission of Paragraph IV certifications, which explicitly identified the asserted patents. Compl. ¶25

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of patent validity. As this is a Hatch-Waxman case triggered by a Paragraph IV certification, the core of the litigation will likely revolve around Cipla's assertions, detailed in its notice letters but not the complaint, that the patents-in-suit are invalid (e.g., for obviousness or lack of enablement) and/or unenforceable. Compl. ¶25
  • A key question for the method-of-use patents ('462, '988, '543) will be one of induced infringement: assuming the patents are found valid, will Cipla's proposed product label be deemed to instruct or encourage administration of semaglutide in a manner that falls within the scope of the asserted claims, or can Cipla successfully design its label to "carve out" the patented uses and dosages?
  • Finally, for the compound patent ('343), a dispositive question is one of claim scope: does the chemical structure of Cipla's active pharmaceutical ingredient fall within the literal scope of the asserted compound claims, a point which is often conceded in ANDA litigation where the focus shifts to validity.
Loading Amended Complaint